Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
6.93
+0.09 (1.32%)
At close: Sep 17, 2025, 4:00 PM EDT
6.98
+0.05 (0.72%)
Pre-market: Sep 18, 2025, 4:53 AM EDT
Bioventus Employees
Bioventus had 930 employees as of December 31, 2024. The number of employees decreased by 40 or -4.12% compared to the previous year.
Employees
930
Change (1Y)
-40
Growth (1Y)
-4.12%
Revenue / Employee
$606,604
Profits / Employee
$1,991
Market Cap
463.56M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 930 | -40 | -4.12% |
| Dec 31, 2023 | 970 | -150 | -13.39% |
| Dec 31, 2022 | 1,120 | -80 | -6.67% |
| Dec 31, 2021 | 1,200 | 500 | 71.43% |
| Dec 31, 2020 | 700 | 50 | 7.69% |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BVS News
- 7 days ago - Bioventus Inc. (BVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference - GlobeNewsWire
- 6 weeks ago - Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Bioventus Reports Second Quarter Financial Results - GlobeNewsWire
- 6 weeks ago - Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity - GlobeNewsWire
- 7 weeks ago - Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products - GlobeNewsWire
- 7 weeks ago - Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 - GlobeNewsWire